English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 2/5 criteria met. Data as of 01/11/2026.
- ✅ Price trend passed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: -68.78%
Price change 2019 → 2020: 167.97%
Price change 2020 → 2021: -14.58%
Price change 2021 → 2022: 31.74%
Price change 2022 → 2023: 26.68%
Price change 2023 → 2024: 182.21%
Price change 2024 → 2025: 109.13%
Price change 2025 → 2026: -77.89%
Price change 2026 (year to date): -77.46%
Financial growth
Revenue CAGR (8 years): -100.00%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.06
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -2.60
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 81.44% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="CAPR" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Capricor Therapeutics, Inc. | – | 0.06 | – | 🔒 |
| Valneva SE | – | 1.95 | +22.4 % | – |
| Lumibird S.A. | 38.1 | 0.71 | +9.8 % | – |
| Equasens S.A. | 10.6 | 0.21 | +6.5 % | – |
| 4D Molecular Therapeutics, Inc. | – | 0.04 | +40.0 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Capricor Therapeutics, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2019 | 1.0 m | -7.6 m | -760.4 % | n/a |
| 2020 | 310,250 | -13.7 m | -4,401.9 % | -69.1 % |
| 2021 | 244,898 | -20.0 m | -8,175.9 % | -21.1 % |
| 2022 | 2.6 m | -29.0 m | -1,137.4 % | +941.8 % |
| 2023 | 25.2 m | -22.3 m | -88.5 % | +886.8 % |
| 2024 | 22.3 m | -40.5 m | -181.7 % | -11.5 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Capricor Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 34.9 m | 41.4 m | 39.5 m | 152 m | 318 m |
| Total Debt | 6.2 m | 5.9 m | 5.6 m | 4.8 m | 17.9 m |
| Net Debt | -28.6 m | -3.7 m | -9.1 m | -6.5 m | -270 m |
| Equity | 31.4 m | 11.8 m | 22.6 m | 145 m | 306 m |
| Total assets | 41.3 m | 50.1 m | 58.7 m | 170 m | 356 m |
| Operating cash flow | -16.8 m | 4.9 m | -25.6 m | -40.0 m | -69.8 m |
| Investments (capex) | 1.2 m | 3.4 m | 2.0 m | 1.5 m | 11.7 m |
| Free cash-flow | -18.0 m | 1.6 m | -27.6 m | -41.5 m | -72.7 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Capricor Therapeutics, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Capricor Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 10/11/2026. Expected EPS: -0.61.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Capricor Therapeutics, Inc.
What is the Capricor Therapeutics, Inc. share price?
Latest recorded price: 9.00 USD on 06/11/2026, for a market cap of 521 m USD.
What is the revenue of Capricor Therapeutics, Inc.?
22.3 m USD for fiscal year 2024, with net income of -40.5 m USD (net margin -181.7 %).
When does Capricor Therapeutics, Inc. report its next earnings?
The next release is expected on 10/11/2026. EPS expected by analysts: -0.61.
What do analysts say about Capricor Therapeutics, Inc.?
Out of 10 analysts: 8 buy or strong buy, 2 hold, 0 sell or strong sell.
Is Capricor Therapeutics, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US14070B3096).
How many employees does Capricor Therapeutics, Inc. have?
160 full-time employees according to the latest published profile.
Who runs Capricor Therapeutics, Inc.?
Linda Marbán is the company's chief executive.